• Alps Group launched an internal patient-derived organoid program, expanding into precision oncology testing for personalized cancer treatment.
• Research and collaboration agreement signed with Kong Wai Mun, executive director of Axiocell Biotech.
• Project targets Malaysia’s first clinically validated PDO platform, pursuing MREC ethics approval plus Medical Device Authority registration.
• Plan includes building a national PDO biobank to support preclinical drug screening services for pharmaceutical companies and CRO partners.
• Initial clinical interest identified across six major oncology centers in Malaysia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alps Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029779), on June 23, 2026, and is solely responsible for the information contained therein.